This email was circulated to BAD members at the request of Dr Cate Orteu, Specialised Dermatology Clinical Reference Group Chair 2019
This email is particularly aimed at those of you involved in the care and treatment of patients with SLE.
It seems that the take up for belimumab treatment is lower than expected and this is a reminder of how to access it for our patients.
There is a managed access agreement (MAA) making funding is available from NHS England for up to 300 patients. This applies until October 2020. As of March 2019, only 113 or the proposed 300 patients had started treatment in England.
Consideration could be given to using belimumab before rituximab in suitable patients. Please see the attached letter here for further details.